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A large array of antigens that are recognized by tumor-specific T cells has been identified 
and shown to be generated through various processes. We describe a new mechanism 
underlying T cell recognition of melanoma cells, which involves the generation of a major 
histocompatibility complex class I–restricted epitope after tumor-mediated uptake and 
processing of an extracellular protein—a process referred to as cross-presentation—which is 
believed to be restricted to immune cells. We show that melanoma cells cross-present, in an 
 
 
 
v
 
 
 
3-dependent manner, an antigen derived from secreted matrix metalloproteinase–2 
(MMP-2) to human leukocyte antigen A*0201-restricted T cells. Because MMP-2 activity is 
critical for melanoma progression, the MMP-2 peptide should be cross-presented by most 
progressing melanomas and represents a unique antigen for vaccine therapy of these 
tumors.
 
Antigens recognized on tumor cells by CTLs
consist of peptides presented by MHC class I
molecules (1). These peptides originate in the
tumor cell cytosol from the degradation of re-
cently translated endogenous proteins, mainly
by the proteasome. Most peptides are trans-
ported into the endoplasmic reticulum where
they are loaded onto MHC class I molecules
and then translocated to the cell surface as
MHC–peptide complexes. It is assumed that
those peptides also may be cross-presented in
vivo by APCs (i.e., loaded onto MHC class I
molecules from internalized tumor proteins),
which could lead to the subsequent induction
of tumor immunity (2, 3).
During the last 14 yr, a large array of human
melanoma–associated antigens has been identi-
fied. Among these, several shared melanoma
antigens have been targeted in immunization
strategies. However, the therapeutic efficacy of
this approach remains limited, despite signifi-
cant induction of tumor-specific T cells (4, 5).
One possible explanation is that targeted antigens
are not suitable to induce efficient immune re-
sponses, which might be due, in part, to the
generation of antigen-loss variants (6). A way
to circumvent this limitation is to vaccinate
against antigenic proteins whose expression is
critical for tumor growth or invasiveness. In an
attempt to identify such tumor cell proteins,
we aimed at characterizing the antigens recog-
nized by tumor-infiltrating lymphocytes (TILs)
infused between 6 and 8 yr ago into patients
who had melanoma who remain tumor-free
(7, 8).
Here we show that the secreted matrix
metalloproteinase–2 (MMP-2) is a novel shared
melanoma antigen that is recognized by TILs
in the HLA-A
 
*
 
0201 context. We also describe
a new mechanism for the generation of this
tumor epitope: cross-presentation, which is
believed to be restricted to immune cells.
 
RESULTS
M134.12 T cell clone recognizes a shared 
melanoma antigen presented on HLA-A*0201
 
One CD8
 
 
 
 TIL clone from the M134 patient
(M134.12) killed the autologous M134 mela-
noma cell line and was able to secrete TNF,
IFN-
 
 
 
, and IL-2 when incubated with this
cell line (Fig. 1 A and not depicted). To iden-
tify the restricting HLA allele, we used a
panel of 29 allogenic melanoma cell lines that
shared at least one HLA allele with the M134
cell line (HLA-A
 
*
 
0201, B
 
*
 
0801, Cw
 
*
 
0701).
Half of HLA-A
 
*
 
0201
 
 
 
 (12 out of 24), but
none of HLA-A
 
*
 
0201
 
 
 
, cell lines were rec-
ognized by M134.12 (Fig. 1 A and not de-
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picted), which indicated that this CTL recognized a shared
melanoma antigen presented by HLA-A
 
*
 
0201. Moreover,
the CTL clone killed freshly isolated HLA-A
 
*
 
0201
 
 
 
 mela-
noma cells (Fig. 1 B).
 
MMP-2 is the antigen recognized by the CTL clone M134.12
 
Because M134.12 CTL did not recognize any of 54 previ-
ously identified tumor antigens, tested by expression in
COS-7 cells (unpublished data), a cDNA library was made
Figure 1. The MMP-2 peptide560-568 is the epitope recognized in 
the HLA-A*0201 context by the M134.12 CTL. (A) TNF response of 
the M134.12 CTL clone to HLA-A*0201 melanoma cell lines. 104 CTLs were 
added to 3.104 melanoma cells, and the TNF content of the supernatant 
was tested after 6 h on WEHI-13 cells. (B) Lysis of freshly isolated HLA-A*0201 
melanoma cells by the CTL clone (the number of passages after isolation is 
indicated in parentheses). M102 and FM29 melanoma cell lines were used 
as negative and positive controls, respectively. 51Cr-labeled tumor cells 
were cocultured with T cells at various effector/target ratios (E/T). Chro-
mium release in the supernatants was measured after 4 h of incubation. 
(C, D) M134.12 CTL responses to COS-7 cells (E/T 1:3) transfected with 
indicated plasmids. CTLs were added 2 d after the transfection, and the 
TNF content of the supernatant was estimated 6 h later by testing the 
toxicity of WEHI-13 cells. (E) The MMP-2 epitope was determined by cyto-
toxicity to peptide-pulsed T2 cells. Target cells were chromium labeled and 
incubated for 30 min with the peptides at the indicated concentrations. 
The CTL clone was added at an E/T ratio of 10:1. Chromium release was 
measured after 4 h. 
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from M134 melanoma mRNA. Plasmid DNA extracted
from pools of bacterial colonies from this library was
cotransfected with HLA-A
 
*
 
0201 into COS-7 cells. After 48 h,
M134.12 T cells were added and TNF production was
assayed. One plasmid pool proved positive in this test, and
the individual plasmid coding for the recognized antigen
was recovered from it after cloning (Fig. 1 C). It contained
a 1.3-kb cDNA insert (hereafter referred to as NA134-A),
which corresponded to the end of the MMP-2 gene tran-
script. To identify the MMP-2 epitope, HLA-A
 
*
 
0201 and
truncated variants of the cDNA NA134-A were cotrans-
fected into COS-7 cells. The stimulatory region mapped
between amino acid 556 and 593 of the MMP-2 sequence
(Fig. 1 D). By screening synthetic peptides spanning this re-
gion, the 9-mer peptide MMP2
 
560-568
 
 (GLPPDVQRV) was
found to be the epitope recognized by M134.12 T cells
(Fig. 1 E).
 
Presentation of the MMP-2 epitope is restricted to 
melanoma cell lines
 
MMP-2 is expressed frequently by normal and tumor cells
(9, 10). Accordingly, MMP-2 expression was demonstrated
first in a panel of 29 normal and malignant HLA-A
 
*
 
0201
 
 
 
cell lines through RT-PCR (Fig. 2), immunocytochemistry,
and zymography analysis (Table I and not depicted).
M134.12 T cells recognized 10 out of 15 HLA-A
 
*
 
0201
 
 
 
/
MMP-2
 
 
 
 melanoma cell lines (Table I and Fig. 1 A). In
contrast, 20 HLA-A
 
*
 
0201
 
 
 
/MMP-2
 
 
 
 nonmelanoma cell
lines—tumoral and normal—were not recognized by this
CTL (Table I). Therefore, the presentation of the 9-mer
MMP-2 peptide on HLA-A
 
*
 
0201 seems to be a unique
property of melanoma cell lines.
 
The MMP-2 epitope is not presented by 
the endogenous pathway
 
Some HLA-A
 
*
 
0201
 
 
 
 melanoma cells (M88, M101, and
M117) and many nonmelanoma cells synthesized MMP-2
but failed to be recognized spontaneously by the M134.12
CTL clone (Table I), whereas they were recognized after
peptide pulse (not depicted). Therefore, we wondered
whether this could be due to a low level of MMP-2 expres-
sion in these cell lines. To address this question, we mea-
sured MMP-2 expression using semi-quantitative RT-PCR
and protein release using an ELISA. Although several cell
lines (M17, M113, M147, FM25, and FM29) that present
the epitope showed a weak MMP-2 expression, some cell
lines that failed to present this epitope had a relatively high
MMP-2 transcription level (M101, M71, F257, and
HAEC#8186; Fig. 2 and Table I). There is no correlation
between mRNA transcription and peptide presentation.
Therefore, we compared MMP-2 protein secretion with
peptide presentation. Data show that at least two melanoma
cell lines (M88 and M101) did not present the MMP-2
epitope although they secrete high amounts of the MMP-2
protein. Another cell line, M117, not recognized by the
CTL clone was shown to express the MMP-2 protein by
immunocytochemistry. Two other cell lines not recognized
(M71 and M74) expressed MMP-2 mRNA but there is no
evidence of protein synthesis because zymography and
ELISA were negative (Table I). Therefore, at least three
melanoma cell lines and many nonmelanoma cell lines (nor-
mal or tumoral) clearly synthesized the MMP-2 protein but
failed to present the epitope (Table I). Therefore, we
checked whether this could be due to the presence of muta-
tions affecting the epitope coding region of MMP-2. To this
end, we sequenced an 800-bp long cDNA epitope-coding
region in three of these cells (M88, M117, and OVCAR).
No mutation was found in these cDNA (unpublished data),
which suggested that these cells express the wild-type
MMP-2, and that the MMP-2 epitope could not be pro-
cessed from it by the classic endogenous road. In support of
this hypothesis, we observed that transfection of the full-
length MMP-2 in HLA-A
 
*
 
0201
 
 
 
 COS-7 cells or in tumor
cell lines not recognized by the CTL clone failed to sensitize
Figure 2. Expression of the MMP-2 gene transcript. mRNAs were 
extracted from tumor or normal cell lines before retro-transcription and 
MMP-2–specific amplification was performed for 27 cycles as described in 
Materials and methods.
Figure 3. The MMP-2 epitope is not presented from full-length 
MMP-2. The M134.12 CTL was cocultured with HLA-A*0201  COS-7 cells 
or tumor cell lines transfected with plasmids coding for the full-length 
MMP-2 or the NA134-A fragment of MMP-2. 104 CTLs were added to 
3.104 target cells, and the TNF content of the supernatant was tested after 
6 h on WEHI-13 cells. 
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Table I.
 
MMP-2 expression and CTL recognition of tumor and normal cell lines
 
MMP-2 expression
Target cells
M134.12
recognition 
(TNF production) RT-PCR
Immunocyto- 
chemistry
MMP-2 release 
(zymography)
ELISA
(supernatants)
 
% ng/mL
 
Tumor
cells
 
melanoma M17
 
 
 
1
 
  
 
/
 
 
 
UND
M113
 
 
 
10
 
  
 
1
M119
 
 
 
56 ND
 
 
 
2
M134
 
 
 
100 (ref.)
 
  
 
50
M147
 
 
 
6,5
 
  
 
13
M153
 
 
 
16
 
  
 
2
M204
 
  
 
100
 
  
 
29
FM25
 
 
 
3
 
  
 
/
 
 
 
UND
FM29
 
 
 
13
 
  
 
1
IPC 277/5
 
 
 
37
 
  
 
31
M71
 
 
 
63 ND
 
 
 
UND
M74
 
 
 
16 ND
 
 
 
UND
M88
 
 
 
13
 
  
 
14
M101
 
 
 
85 ND
 
 
 
64
M117
 
 
 
29
 
  
 
UND
M102
 
 
 
0
 
  
 
UND
lung 1355
 
 
 
7
 
  
 
/
 
 
 
5
Bla-2
 
 
 
0 ND ND UND
Heu-n
 
 
 
6N D
 
 
 
/
 
 
 
UND
734-B
 
 
 
0N D
 
 
 
UND
MDAMB-231
 
 
 
0N D
 
 
 
UND
neuroblastoma LAN-1
 
 
 
6
 
  
 
UND
colo205
 
 
 
0N D
 
 
 
UND
C4A
 
 
 
0N D
 
 
 
UND
HCT116
 
 
 
2N D
 
 
 
/
 
 
 
UND
Sw480
 
 
 
10
 
  
 
UND
Sw620
 
 
 
0N D
 
 
 
UND
Sw707
 
 
 
ND ND
 
 
 
UND
Sw1116
 
 
 
0N D
 
 
 
UND
renal cell
carcinoma
A498
 
 
 
3
 
  
 
UND
R28
 
    
 
ND ND
ovary OVCAR
 
 
 
9
 
  
 
/
 
 
 
1
thyroid TT
 
 
 
3    UND
myeloma U266   0    UND
Normal
cells
melanocyte 98M09 (P6)   ND   ND
01M08 (P4)   ND   ND
MHN 3 (P1)   ND ND   UND
MHN 5 (P2)   ND ND   UND
keratinocyte K1      ND ND
fibroblast MG    ND ND ND
HFFF2    ND ND ND
F257    100 ND   89
endothelium HAEC#8186    100 ND ND ND
CD8 T cell clones 10C10   5N D   UND
M77.84   3N D   UND
M17.221   3N D   UND
CD4 T cell clone M101.70   20 ND   UND
EBV-B ADAM   0N D   UND
B17   0N D   UND
BM16   0N D   UND
Boleth   0N D   UND
Dabin   0N D   UND
Tumor and normal human HLA-A*0201  cell lines were tested for MMP-2 expression by various approaches as indicated. PCR band intensities were measured individually from 
the original TIFF image (Fig. 2) with NIH image-J software after normalization with  -actin. Results are expressed as a percentage of the level of expression in M134 melanoma 
cell line. For R28, K1, MG, and HFFF2, MMP-2 products were detected, but not quantitated ( ). ELISA and zymography assays from culture supernatants were used for evaluation 
of MMP-2 release. The TNF assay was performed by adding 10,000 lymphocytes to 30,000 target cells and testing the supernatants 6 h later on WEHI-13 cells. The number of 
passages is indicated in brackets for melanocytes.
UND, undetectable.JEM VOL. 202, July 4, 2005 65
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these cells to clone recognition. In contrast, the NA134-A
fragment of MMP-2, transfected in the same conditions, did
sensitize these cells to CTL clone recognition (Fig. 3). These
data show that the absence of MMP-2 peptide presenta-
tion from endogenous or transfected full-length wild-type
MMP-2 by tumor cells does not result from a defect of the
antigen presentation capacity of transfected or spontaneously
expressing cells, but results rather from a general inability of
the classic endogenous processing pathway to generate the
MMP-2 peptide from the full-length protein.
Marie-Hélène   0N D   UND
Marie-Luce   0N D   UND
Grégoire   0N D   UND
Le Pendu   0N D   UND
Table I. MMP-2 expression and CTL recognition of tumor and normal cell lines
MMP-2 expression
Target cells
M134.12
recognition 
(TNF production) RT-PCR
Immunocyto- 
chemistry
MMP-2 release 
(zymography)
ELISA
(supernatants)
Tumor and normal human HLA-A*0201  cell lines were tested for MMP-2 expression by various approaches as indicated. PCR band intensities were measured individually from 
the original TIFF image (Fig. 2) with NIH image-J software after normalization with  -actin. Results are expressed as a percentage of the level of expression in M134 melanoma 
cell line. For R28, K1, MG, and HFFF2, MMP-2 products were detected, but not quantitated ( ). ELISA and zymography assays from culture supernatants were used for evaluation 
of MMP-2 release. The TNF assay was performed by adding 10,000 lymphocytes to 30,000 target cells and testing the supernatants 6 h later on WEHI-13 cells. The number of 
passages is indicated in brackets for melanocytes.
UND, undetectable.
Figure 4. Uptake of soluble MMP-2 leads to peptide presentation 
by melanoma cells. Tumor or normal cell lines and T2 cells were cultured 
with (A) rMMP-2 (100 ng/ml) or (B) an MMP-2–secreting cell line (M88) 
not recognized by the CTL M134.12 (ratio 1:1). The CTL was added the next 
day and corresponding supernatants were tested for TNF content 6 h later 
on WEHI-13 cells. Histologic origins of the cell lines are indicated in Table 
I. The number of passages is indicated in parentheses for melanocytes. 
Standard deviations were obtained from duplicates.
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The MMP-2 epitope presented by melanoma cells comes 
from exogenously acquired MMP-2 protein
Because MMP-2 normally is secreted as a proenzyme, we
addressed a possible requirement for MMP-2 secretion for its
presentation by melanoma cell lines. The data obtained from
zymography assay show that 10 melanoma cell lines recog-
nized by the M134.12 CTL had a gelatinolytic activity in
their supernatant, showing that they secrete proMMP-2,
whereas 4 of the 6 melanoma cell lines which were not
(M71, M71 and M117) or poorly recognized (M17), lacked
or poorly displayed any such activity (Table I). To assess di-
rectly whether secreted MMP-2 could be uptaken, pro-
cessed, and presented to T lymphocytes, we incubated sev-
eral HLA-A*0201  tumor (melanoma and nonmelanoma)
and normal cell lines (freshly isolated melanocytes, fibro-
blasts, and T cell clones), which were not or poorly recog-
nized by the CTL clone, with exogenous MMP-2. These
cell lines were cultured with 100 ng/ml rMMP-2 (Fig. 4 A)
or with the M88 melanoma line that secretes MMP-2 but
does not stimulate the M134.12 CTL (Fig. 4 B). This al-
lowed M17 and M102, but not M117 and nonmelanoma
cell lines, to be sensitized to M134.12 CTL recognition.
Moreover, 10 EBV-B cell lines, incubated with rMMP-2,
did not stimulate the CTL clone (unpublished data). T2 cells
cultured in the same conditions failed to be sensitized to
clone recognition; this showed that melanoma cell sensitiza-
tion did not result from passive binding to HLA-A*0201 of
contaminating peptide fragments in the recombinant protein
preparation (Fig. 4, A and B). Therefore, some melanoma
cell lines are able to process the MMP-2 peptide from an ex-
ogenous supply of the protein and so can perform cross-pre-
sentation. Moreover, this cross-presentation of secreted
MMP-2 seems to be very efficient because it was observed
using the supernatant of a melanoma cell line (M88) that
contained 14 ng/ml of the protein (Fig. 4 B).
MMP-2 epitope presentation is proteasome- 
and clathrin-coated vesicle–dependent
To understand how naturally secreted and exogenous
MMP-2 could be processed and associated to HLA-class I in
melanoma cells, we studied the effect of various inhibitors of
peptide presentation pathways on MMP-2 peptide presenta-
tion by two spontaneously presenting cell line (M134 and
FM29) and by the M102 cell line induced to present the
epitope from an exogenous supply.
Monodansylcadaverine, an inhibitor of clathrin-mediated
endocytosis (11), significantly blocked natural presentation
of the MMP-2 peptide by melanoma cell lines, M134 and
FM29, as well as presentation of added rMMP-2 by the
MMP-2  M102 cell line; however it had no effect on the
presentation of added synthetic 9-mer MMP-2 peptide (ex-
cept at the 100  M concentration, which seemed to be toxic
for the M134 cell line; Fig. 5 A). In contrast, amiloride, an
inhibitor of macropinocytosis; cytochalasin B and D, inhibi-
tors of actin polymerization; ammonium chloride, which
prevents lysosome and endosome acidification; pepstatin A,
which inhibits the cathepsin D enzyme; and leupeptin, an
inhibitor of serine and cysteine proteases, did not alter the
MMP-2 peptide presentation by these melanoma cells (un-
published data). A specific inhibitor of proteasomal activities,
lactacystin (which inhibits tryptic, chymotryptic, peptidyl-
glutamyl peptide hydrolase, and branched chain amino acid–
preferring protease activities) strongly inhibited MMP-2
epitope presentation (Fig. 5 B). Finally, a role of cytosolic
peptidases was addressed: E64, an inhibitor of cysteine pro-
teases (12); alanine-alanine-phenylalanine-chloromethylke-
Figure 5. MMP-2 is processed by a clathrin-coated pits- and
proteasome-dependent pathway. Melanoma cell lines (M134, FM29, 
and M102) were treated overnight with (A) monodansylcadaverine or (B) 
lactacystin. The M102 cell line also was cultured overnight in presence of 
rMMP-2 (100 ng/ml) before the CTL stimulation assay. Cells were washed 
and cocultured with the M134.12 CTL (E/T 1:3) before TNF estimation 6 h 
later on WEHI-13 cells.JEM VOL. 202, July 4, 2005 67
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ton, an inhibitor of tripeptidyl peptidase (TPP) I; TPP II;
bleomycin hydrolase and puromycin-sensitive aminopepti-
dase enzymes (13, 14); and JA-2, an inhibitor of the Thymet
oligopeptidase (15), had no effect on the presentation of the
MMP-2 epitope by melanoma cell lines (unpublished data).
Therefore, endocytosis of exogenous MMP-2 through
clathrin-coated pits and proteasome activity are required for
MMP-2 peptide presentation.
MMP-2 epitope presentation depends on  v 3 expression 
by melanoma cells
For two melanoma cell lines, M88 and M117, as well as for
several nonmelanoma cell lines, spontaneous secretion or ad-
dition of rMMP-2 did not allow their recognition by
M134.12 T cells (Fig. 4, A and B); this suggested the exist-
ence of additional factors which underlie MMP-2 epitope
cross-presentation. Therefore, we asked whether MMP-2
uptake was mediated by a receptor. Because secreted MMP-2
is known to interact with various membrane-bound mole-
cules, such as CD91 (16), membrane type-1 (MT1)-MMP
(17), and  v 3 (18), on tumor cell lines, the role of these
molecules as receptors or cofactors for MMP-2 peptide pre-
sentation was addressed, first, by analyzing the expression of
these molecules in a panel of HLA-A*0201 /MMP-2  cell
lines recognized by the CTL clone. Only the expression of
 v 3 correlated with T cell clone recognition (Table II and
Fig. 6). This suggested that the expression of  v 3, but not
that of CD91 or MT1-MMP, is required for MMP-2
epitope presentation. Therefore, we analyzed the effect of
blocking the  v 3 receptor using a mAb. An anti-CD91
Figure 6.  v 3 expression. Cell lines were stained for 30 min at 4 C 
with an anti- v 3-FITC mAb (23C6, BD Biosciences). Negative controls 
were performed by incubating the cells with isotype-matched FITC control 
antibody. Labeling was analyzed on a FACScan flow cytometer using 
Cellquest software (Becton Dickinson).
Figure 7. MMP-2 peptide presentation depends on  v 3 expression. 
(A) Melanoma cell lines were incubated with anti- v 3 or anti-CD91 
mAb (at indicated concentrations in  g/ml) for 1 h at room temperature. 
The CTL M134.12 was added (E/T ratio 1:3) before estimation of the TNF 
content of the supernatants 6 h later on WEHI-13 cells. The graph is rep-
resentative of four different experiments and standard deviations were 
obtained from duplicates. (B) A plasmid coding for the  3 chain trans-
fected in  v 3 /MMP-2  tumor cell lines with a lipofectamine reagent 
kit. 24 h later, these cell lines were or were not cultured overnight with 
rMMP-2 (100 ng/ml) before CTL stimulation assay. The TNF content of the 
supernatants was tested after 6 h on WEHI-13 cells. Standard deviations 
were obtained from duplicates.CROSS-PRESENTATION OF MMP-2 BY MELANOMA CELLS | Godefroy et al. 68
Table II. MMP-2 interacting molecules expression by target cells
Expression of
 v 3
Target cells
M134.12 
recognition 
(TNF production)
CD91 
(Ab staining)
MT1-MMP 
(RT-PCR)
 3 chain 
(RT-PCR) 
Ab staining
(RFI)
%
Melanoma cells M17   ND  /  84 6.6
M113   ND   182 4.6
M119   ND ND 34 3.7
M134    /   100 (ref.) 3.5
M147    /   57 2.5
M153    /   /  113 4.7
M204      67 7.6
FM25   ND   126 1.8
FM29      37 6.3
IPC 277/5   ND  /  143 3.6
M71   ND ND 54 3.3
M74   ND ND 14 3.5
M88    /  6 1.1
M101   ND ND 7 1.3
M117    /   249 1.3
M102      96 3.2
Nonmelanoma
tumor cells
1355    /  41
Bla-2   ND ND 4 2
Heu-n   ND ND 0 1
LAN-1   ND ND 0 1
HCT116   ND ND 0 1
Sw480      01
Sw707   ND ND 0 1
A498      58 5.5
R28   ND   ND ND
OVCAR   ND   51
TT   ND   01
Normal cells 98M09 (P6)   ND ND ND 1.3
01M08 (P4)   ND ND ND 1.2
MHN 3 (P1)   ND ND ND 1.1
MHN 5 (P2)   ND ND ND 1
K1   ND ND ND ND
MG   ND ND ND ND
HFFF2   ND ND ND 1
F257   ND ND 5 1.2
HAEC#8186   ND ND ND ND
10C10   ND ND 0 1
M77.84   ND ND 0 1
M17.221   ND ND 0 1
M101.70   ND ND 0 1
Tumor and normal human HLA-A*0201 /MMP-2 cell lines and the M102 melanoma cell line (HLA-A*0201 /MMP-2 ) were tested for MMP-2 interacting molecule expression 
by RT-PCR (MT1-MMP and  3) or by antibody staining (anti- v 3 [23C6] and anti-CD91 [A2MR- 2]). For  3, PCR band intensities were measured individually from the original 
TIFF image with NIH image-J software after normalization with  -actin. Results are expressed as a percentage of the level of expression in M134 melanoma cell line. To evaluate 
the level of  v 3 expression, we determined RFI values as described in Material and methods. See Table I for the cell nature and origin.JEM VOL. 202, July 4, 2005 69
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was used as a control. The anti- v 3, but not the anti-
CD91, antibody inhibited MMP-2 peptide recognition of
 v 3  melanoma cell lines, M134 and FM29, and of the
M102 cell line cultured with rMMP-2 (Fig. 7 A). Con-
versely, transfection of a plasmid coding for the  3 chain in
melanoma cell lines, M88 and M117, and also in the non-
small cell lung carcinoma 1355 cell line, sensitized these cells
to M134.12 CTL recognition, directly for M88 and 1355 or
in the presence of rMMP-2 for M117 that did not secrete
this protein (Fig. 7 B). Therefore, the presentation of MMP-2
epitope on HLA-A*0201  tumor cells seems to depend on
the expression of  v 3 by these cell lines.
To document better the expression of this molecule, we
performed a systematic measurement of  3 and  v 3 ex-
pression in cell lines expressing the MMP-2 transcript, by
semi-quantitative RT-PCR of the  3 chain and immuno-
fluorescence of the entire integrin, respectively (Table II).
Data show that high amounts of  3 transcript were found in
melanoma cells but also in one renal cell carcinoma line,
A498 (Table II). No correlation was observed between  3
mRNA levels and cell surface expression of  v 3 (Table II).
This could be due to posttranscriptional regulation of the  3
chain expression or to the formation of other heterodimers
with one of these two chains, such as  v 5 or  IIb 3 (19).
Most cell lines expressing the MMP-2 epitope (with the ex-
ception of FM25) seem to express the  v 3 integrin at
higher levels than cell lines that do not present it (Table II).
Therefore, the restricted expression of MMP-2 epitope by
melanoma cells should be related, in part, to the unique ca-
pacity of these cells to express significant levels of  v 3 on
their surface.
DISCUSSION
Here we showed that an HLA-A*0201–restricted peptide
from the MMP-2 may be cross-presented by  v 3 -
expressing tumor cells following clathrin-coated pits–medi-
ated uptake of extracellular MMP-2 and proteasome activity.
The endogenous classic cytosolic pathway did not present this
peptide. The HLA-A*0201–cross-presented MMP-2 pep-
tide was identified as the epitope recognized by a CTL clone
present among the TILs of a patient who had melanoma and
received passive transfer of autologous tumor-reactive TILs 8
yr ago and who remains tumor-free (7, 8). Whether this
clone had taken part in a protective antitumor response is
unknown, but this lytic activity should occur in vivo because
the CTL clone killed freshly isolated melanoma cells from
this patient. Using HLA-A*0201/MMP-2560-568 tetramers,
we recently found MMP-2–specific lymphocytes among the
TILs from 5 out of 32 patients who were treated in the same
clinical assay (Godefroy et al., unpublished data).
Our results demonstrate for the first time that cross-pre-
sentation is used by melanoma cells for the generation of
class I–restricted antigens, a mechanism that is believed to be
essentially restricted to immune cells. Moreover, cross-pre-
sentation of secreted MMP-2 seems to be very efficient be-
cause it was observed using the supernatant of a melanoma
cell line (M88) that contained 14 ng/ml of the protein,
whereas OVA peptide cross-presentation through FcR-
dependent internalization required OVA concentrations that
ranged from 0.1 to 1  g/ml (20).
MMP-2, also known as gelatinase-A or type IV collage-
nase, is a proteolytic enzyme that is secreted by normal and
tumor cells; essentially, it degrades components of the extra-
cellular matrix, basal membranes, and specific cell modulators
(9). It is secreted as a latent proenzyme comprising four do-
mains: a peptide secretion domain, a prodomain, a catalytic
domain, and a COOH-terminal hemopexin-like domain.
MMP-2 becomes active extracellularly by cleavage of its pro-
domain after interactions with membrane-bound MT1-MMP
and soluble tissue inhibitors of metalloproteinase-2; reference
17). Secreted MMP-2 also interacts with other membrane
proteins, such as the CD91/thrombospondin-2 complex (16),
and with integrins, including  v 3 (18, 21, 22); this restricts
the area of MMP-2 activity and regulates extracellular MMP-2
levels through receptor-mediated uptake.
The epitope identified here is localized in the he-
mopexin-like domain of MMP-2 that is shown to interact
with  v 3 (22). Previous studies of the same group and oth-
ers showed that  v 3 is a receptor of melanoma cells for ac-
tive MMP-2 (18), whose expression level in these tumors
correlates with progression and metastasis (10, 23, 24). We
provide experimental evidence that this integrin is involved
in MMP-2 peptide cross-presentation, possibly by mediating
MMP-2 uptake.
We showed also that MMP-2 peptide presentation de-
pends on clathrin-coated vesicles and proteasome. This
raised the question of how MMP-2 could reach the protea-
some following endocytosis. Available knowledge on anti-
gen processing suggests that this should involve a retrotrans-
location from the endosome to the cytosol, possibly by the
ER membrane Sec61 pore complex or the Derlin complex
(25, 26). This implies that internalized MMP-2 gains access
to the ER by transiently available continuities with the lu-
men of the endosome (in this case, cross-presentation could
occur in the ER proper; 27–29), or that the MMP-2–con-
taining endosome is self-sufficient for mediating cross-pre-
sentation, incorporating Sec61, associated proteasomes, and
peptide-loading complexes (27, 30).
Tumor cells that expressed the MMP-2 protein but failed
to secrete it (M117, Sw480, A498, OVCAR, TT), or those
that secreted MMP-2 but lacked the  v 3 integrin (M71,
M74, M88, 1355), did not present the MMP-2 epitope.
Nevertheless, some of these tumor cells could be sensitized
by the addition of exogenous MMP-2 or by transfection of a
plasmid coding for the  3 chain. Therefore, in contrast with
other HLA class I–restricted tumor epitopes, the MMP-2
peptide cannot be processed from the native intracellular
MMP-2 through the classic endogenous pathway. One likely
explanation is that native MMP-2 escapes from protease deg-
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its sequence, conformation, or localization. proMMP-2 con-
tains a secretion peptide and a prodomain that are absent in
the NA134-A peptide. Disulphide bonds and  -helical
stretches, located in the prodomain (31), could be responsible
for the absence of MMP-2 epitope generation by the endog-
enous pathway (32, 33). Alternatively, the secretion peptide
could segregate native MMP-2 from the cytosol, and prevent
its access to the proteasome (34). Whatever mechanism un-
derlies defective presentation of the MMP-2 epitope by the
endogenous road, MMP-2 needs to be secreted, internalized,
and processed for peptide presentation.
Cutaneous melanoma is a highly invasive and metastatic
tumor. Degradation and remodeling of the extracellular ma-
trix and basement membranes by MMP-2 are essential steps in
these processes that depend essentially on the coordinated
production of active MMP-2 by tumor or stromal cells, and
expression of  v 3 by melanoma cells (24, 35–37). There-
fore, most progressive HLA-A*0201 melanoma cells should
cross-present the MMP-2 peptide both from the MMP-2
they secrete, as melanoma cell lines do in vitro, and from the
one secreted by the surrounding stromal cells. This should al-
low higher in vivo MMP-2 epitope presentation by these
melanoma cells than in vitro by tumor cell lines. Although
many normal and tumor tissues express MMP-2, we observed
that melanoma cell lines only did present the MMP-2
epitope. This might be due to a restricted coexpression of
MMP-2 and  v 3 by these cells. Therefore, MMP-2 seems
to be a melanoma-specific antigen. Hence, this antigen could
be a relevant target for immunotherapy of HLA-A*0201 mel-
anoma patients. Nonetheless, an appropriate animal model
will be necessary to confirm the restricted expression of the
MMP-2 peptide to melanoma cells and to assess the potential
autoimmune risk associated with MMP-2 vaccination.
Because MMP-2 plays a key role in tumor angiogenesis,
growth, and metastasis (22, 38–40), synthetic and natural
MMP inhibitors have been used for anti-tumor therapies.
Despite disappointing clinical results it is hoped that MMP
inhibitors might be efficient anti-invasive agents at early dis-
ease stages or as adjuvant treatments (10, 41). Recent studies
supported an anti-invasive effect of the PEX peptide (42).
Because the MMP-2560-568 epitope is contained within the
PEX  v 3 interacting sequence of MMP-2, vaccines con-
taining such a sequence, or a recombinant DNA which en-
codes it, could, induce an antimelanoma invasive effect and
T cell–mediated responses against the MMP-2 epitope by
competing with MMP-2 binding. Such vaccines also should
have the unique property of simultaneously inducing, or in-
creasing, epitope presentation on the tumor target cells and
stimulating T cell responses.
Finally, because MMP-2 also was reported to play a role
in tumor-mediated immunosuppression through the pro-
teolytic cleavage of the IL-2R  that is expressed by tumor
reactive T cells (43), MMP-2 vaccines that are able to inhibit
MMP-2 activity also should potentiate the vaccine effect by
avoiding growth factor starvation of activated T cells.
In conclusion, the present data suggest that MMP-2 is a
unique tumor antigen for vaccine therapy of invasive mela-
noma tumors because it opens the way for innovative strate-
gies that combine vaccine and anti-invasive therapeutic
approaches for the treatment of patients who have HLA-
A*0201 melanoma. More generally, the demonstration that
melanoma cells can perform cross-presentation—a process
which is believed to be restricted to immune cells—raises the
possibility for redirecting preexisting T cells responses that are
specific for common environmental antigens against mela-
noma cells, through immunization against proteins fused to
 v 3 noncatalytic binding fragments of MMP-2.
MATERIALS AND METHODS
Cell lines and TIL cultures. The CTL clone, M134.12, was isolated
from a tumor-invaded lymph node of patient M134 who had melanoma.
This patient had been included in a clinical trial consisting of TILs plus IL-2
infusions (7). This protocol was approved by the Institutional Ethics Com-
mittee and registered with regulatory state authority. Melanoma (M), colo-
rectal cancer (C) and renal cell carcinoma cell lines (R) were established
from metastatic tumors or tumor invaded–lymph node fragments that were
obtained after patient’s consent. The various cell lines that were used in this
study have been published (44–46). Melanoma cell lines, FM25 and FM29,
were gifts from J. Zeuthen (Danish Cancer Society Research Center,
Copenhagen, Denmark). Ovary, neuroblastoma, renal carcinoma, and thy-
roid cell lines (OVCAR, LAN-1, A498, and TT, respectively) were gifts
from C. Saï (INSERM U601, Nantes, France). Colorectal carcinoma
(Sw480, Sw620, Sw707, Sw1116, HCT116, colo205), lung carcinoma
(Heu-n and Bla-2), and breast carcinoma cell lines (MDAMB-231, 734-B)
were gifts from M. Grégoire (INSERM U601, Nantes, France), S. Chouaib
(INSERM U487, Villejuif, France), and D. Jäger (Klinik und Poliklinik für
Onkologie, Zürich, Germany), respectively. K1 keratinocyte cell line was
prepared from foreskin fragments of healthy donors that were incubated
overnight in trypsin at 4 C. Normal melanocytes, MHN 3 and MHN 5,
were gifts from S. Tartare-Deckert (INSERM U597, Nice, France). Nor-
mal melanocytes (98M09 and 01M08), fibroblasts (MG and HFFF2), EBV-B
cell lines, and endothelial cell lines (HAEC#8186), were gifts from M.
Regnier (L’Oréal Laboratory, Paris, France), M. Grégoire (INSERM
U601, Nantes, France), H. Vié (INSERM U601, Nantes, France) and B.
Charreau (INSERM U643, Nantes, France), respectively. Tumor cells
were treated with lactacystin, epoxomicin, E-64, amiloride, monodansylca-
daverine, cytochalasins B and D, ammonium chloride, pepstatin A, leupep-
tin (Sigma-Aldrich), AAF-CMK (Tebu), and JA-2 (I. Smith, Baker Medical
Research Institute, Melbourne, Australia), overnight at 37 C.
cDNA library. Poly-A  RNA was extracted from M134 cells using the
Fast Track 2.0 mRNA extraction kit (Invitrogen) and converted to cDNA
using a cDNA synthesis kit (Stratagene). cDNA were ligated to EcoRI adap-
tors, digested with XhoI, and inserted at the EcoRI and XhoI sites of expres-
sion vector pcDNA3.1 (Invitrogen). Recombinant plasmids were electropo-
rated into Escherichia coli XL1 (Stratagene). For screening, 574 pools of 100
ampicillin-resistant bacteria were constituted. Plasmid DNA was extracted
from each pool with the QIAprep Spin Miniprep kit (QIAGEN).
The positive plasmid was opened with XbaI and XhoI and digested
with exonuclease III with the Erase-a-base System before ligation
(Promega) to define the region coding for the epitope.
cDNA sequencing. cDNA were sequenced by the dideoxy chain termi-
nation method (USB). NA134-A corresponded to the end of the MMP-2
sequence (PubMed/blast accession no. NM_004530).
Transient transfection of COS-7 cells and tumor cell lines. Trans-
fection of COS-7 cells was performed by the DEAE-dextran-chloroquineJEM VOL. 202, July 4, 2005 71
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method, as described (47). Tumor cells were transfected with a lipo-
fectamine reagent kit (Invitrogen), according to the manufacturer’s instruc-
tions. The  3-GFP plasmid was provided by B. Ihmof (Pathology Depart-
ment, Geneva, Switzerland).
Synthetic peptides. The MMP-2 peptides were purchased from Synt:em
and were  85% pure by reversed-phase HPLC. Lyophilized peptides were
dissolved in water containing 0.1% trifluoroacetic acid at 10 mM and stored
at  80 C. Cell lines were pulsed for 1 h at 37 C with peptides and washed.
T cell stimulation assays. For the TNF assay, T cells (104) were added to
3.104 stimulator cells (cells transfected for 48 h or tumor and normal cell
lines). Culture supernatants, harvested 6 h later, were tested for TNF content
by measuring lysis of WEHI 164 clone 13 in an MTT colorimetric assay (48).
The chromium release assay was performed as described elsewhere
(46). In brief, 103 or 3.103 51Cr-labeled target cells (peptide-pulsed T2 cells
or tumor cells, respectively) were cocultured with T cells at various effec-
tor/target ratios. Chromium release in the supernatants was measured after
4 h of incubation.
For blocking assays, target cell lines were incubated 1 h at room temper-
ature with anti- v 3 or anti-CD91 (respectively 23C6 and A2MR- 2, BD
Biosciences) at indicated concentrations before CTL addition and TNF assays.
Sensitization of melanoma cell lines to CTL clone recognition was per-
formed by overnight incubation in 96-well rounded bottom plates at 37 C
with recombinant MMP-2 (rMMP-2; 100 ng/ml; BIOMOL Research
Laboratories, Inc.) or the MMP-2 secreting melanoma cell line, M88 (ratio
1:1), not recognized by the CTL clone.
RT-PCR assays. Total RNA was extracted using the Trizol reagent
(GIBCO BRL), according to the manufacturer’s instructions, and was used
for cDNA synthesis (49).
For amplification of MMP-2 cDNA, PCR assays were performed with
primers 5 -TGGGCAACAAATATGAGAGC-3  and 5 -CGGCATC-
CAGGTTATCGGGG-3  (792 bp), for 27 cycles (1 min at 94 C, 1 min at
60 C, and 1 min at 72 C). For amplification of  3 cDNA, PCR assays were
performed with primers 5 -TGAGAAGTGCCCCACCTG-3  and 5 -
TGGCTGTGTCCCATTTTGC-3  for 27 cycles (1 min at 94 C, 1 min at
60 C, and 1 min at 72 C). Samples were normalized for RNA and cDNA
integrity and quantity by PCR amplification of human  -actin cDNA (49).
For semi-quantitative expression measurements, cDNA was synthe-
sized as above. RNA obtained from M134 cells was used undiluted or was
diluted serially in E. coli tRNA for each series of quantitative PCR.
Immunocytochemistry. Cells were spread on slides (500 revolutions/
min for 5 min), fixed with acetone (10 min), and incubated successively
with a MMP-2–specific antibody (5  g/ml; CA4001; Serotec), before using
the Dako-ChemMate kit (DakoCytomation) according to the manufac-
turer’s instructions. Counter-staining was performed with hematoxylin.
ELISA assays. Release of MMP-2 by cell lines was quantitated by an
ELISA kit (Calbiochem) according to the manufacturer’s instructions. This
“sandwich” enzyme immunoassay was performed on conditioned media
obtained from cell lines (3.105 cells) cultured with RPMI 1640 medium
(300  l) without stromal-vascular fraction in 24-well plates for 48 h.
Gelatin substrate gel zymography. Secretion of MMP-2 was evaluated
by gelatin zymography, as described previously (50). Conditioned media,
obtained from cell lines (3.105 cells) cultured with RPMI 1640 medium
(300  L) without stromal-vascular fraction in 24-well plates for 48 h, were
mixed with SDS buffer without reducing agent, and proteins were sub-
jected to SDS-PAGE in 7.5% polyacrylamide gels containing gelatin at 1
mg/ml. After electrophoresis, SDS was removed from the gel by incubation
in 2.5% triton X-100 for 1 h at room temperature. The gels were incubated
in a buffer containing 50 mmol/L Tris-HCl, 5 mmol/L CaCl2, pH 7.6, for
24 h at 37 C. The gels were stained with coomassie blue R250. Proteolytic
activities were evidenced as clear bands against the blue background of
stained gelatin.
Immunostaining of cell lines. Tumor and normal cell lines were ana-
lyzed for surface molecule expression by direct or indirect immunofluores-
cence and flow cytometric analysis. In brief, 105 cells were stained with the
corresponding mAb (anti- v 3 [23C6, BD Biosciences]) and anti-CD91
(A2MR- 2, BD Biosciences) for 30 min at 4 C. Negative controls were per-
formed by incubating the cells with isotype-matched control antibody. For
indirect staining, cells were incubated for 30 min with the secondary PE-
labeled antibody. Labeling was analyzed on a FACScan flow cytometer using
Cellquest software (Becton Dickinson). 10,000 cells were gated with FSC/
SSC parameters and analyzed. The ratio of fluorescence intensity was calcu-
lated for  v 3 expression as follows: mean fluorescence intensity obtained
with the test/mean fluorescence intensity obtained with the negative control.
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